Key Highlights
- President Trump issued an executive order mandating expedited review processes for psychedelic therapeutics, sparking a sector-wide rally.
- Enveric Biosciences (ENVB) stock exploded over 160% during trading, establishing itself as the top performer among psychedelic biotechnology companies.
- The administration pledged $50 million specifically for ibogaine studies, targeting PTSD treatments despite its Schedule I classification.
- Major industry players including Compass Pathways (CMPS) up 26.1%, AtaiBeckley (ATAI) up 28.1%, and GH Research (GHRS) rising nearly 20% joined the rally.
- RBC’s Brian Abrahams characterized the order as “a substantial step towards diminishing regulatory risk” across the psychedelic medicine sector.
The psychedelic biotechnology sector experienced a dramatic surge Monday following President Trump’s weekend executive order commanding federal health authorities to accelerate approval pathways for psychedelic-derived therapies. Leading the explosive rally was Enveric Biosciences (ENVB), which closed trading with gains exceeding 160% — a remarkable jump for a company carrying a market capitalization of merely $3.43 million.
Enveric Biosciences, Inc., ENVB
The executive order avoided naming specific companies, instead issuing sweeping instructions to the FDA and associated regulatory bodies to streamline approval processes for psychedelic medications. The announcement alone proved sufficient to ignite a sector-wide surge.
AtaiBeckley (ATAI) soared 28.1% during premarket hours. Compass Pathways (CMPS) climbed 26.1%. Definium Therapeutics (DFTX) posted gains of 14.6%. GH Research (GHRS) advanced 19.7%. The momentum rippled across the entire industry quickly and decisively.
Presidential Commitment: $50M for Ibogaine Studies
Along with the regulatory directive, President Trump announced a $50 million commitment specifically for ibogaine research initiatives. Ibogaine, a psychoactive substance extracted from West African plants, currently holds Schedule I status under federal law — designating it as having no accepted medical application.
This funding commitment represents a meaningful pivot in the administration’s approach to mental health care, particularly regarding post-traumatic stress disorder treatment. Early-stage research has demonstrated ibogaine’s potential efficacy for PTSD, with particular relevance for military veteran populations.
Compass Pathways CEO Kabir Nath publicly praised the executive action, stating it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” RBC analyst Brian Abrahams reinforced this sentiment, characterizing the directive as “a substantial step towards diminishing regulatory risk” facing psychedelic pharmaceutical development.
ENVB’s explosive price movement carried additional significance. Just days before, the company successfully completed a $5 million private placement offering — a capital raise that actually exceeded the firm’s total market capitalization at that moment. The offering consisted of 2,222,223 shares priced at $2.25 apiece, accompanied by two warrant series exercisable at $2.00 per share.
Pipeline Development and Intellectual Property Advances
The company’s primary drug candidate, designated EB-003, targets both 5-HT2A and 5-HT1B receptor systems and is under development for various psychiatric and neurological indications. Recently disclosed mechanistic findings demonstrated that EB-003 activates dual signaling cascades associated with antidepressant and anxiolytic therapeutic effects.
ENVB has also recently secured U.S. patent protection covering its EVM301 molecular series, which encompasses EB-003, alongside Canadian trademark approvals for five proprietary marks including “Enveric” and “Next Generation Mental Health.”
Should both warrant series from the private placement reach full exercise, the company stands to generate an additional $8.9 million in gross capital.
Monday’s extraordinary price action — surpassing 160% gains — captured both the broader industry momentum triggered by the executive order and the company’s recent capital infusion that extended its operational runway heading into this pivotal moment.
